What's Happening?
Merck has announced that the combination of KEYTRUDA (pembrolizumab) and Padcev (enfortumab vedotin-ejfv) has significantly improved event-free survival (EFS) and reduced the risk of death in patients with muscle-invasive bladder cancer (MIBC) eligible
for cisplatin-based chemotherapy. The Phase 3 KEYNOTE-B15 trial demonstrated a 47% reduction in EFS events and a 35% reduction in mortality risk compared to standard neoadjuvant chemotherapy and surgery. These findings were presented at the 2026 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium.
Why It's Important?
The trial results represent a significant advancement in the treatment of MIBC, offering a new potential standard of care for patients eligible for cisplatin-based chemotherapy. The combination therapy not only extends survival but also improves the quality of life for patients by reducing disease progression and recurrence. This development could lead to broader regulatory approvals and increased adoption of the regimen in clinical practice, potentially benefiting a large number of patients worldwide. The success of this trial also reinforces the role of immunotherapy in cancer treatment, highlighting the potential for combination therapies to enhance outcomes.
What's Next?
Merck plans to share the trial results with regulatory authorities globally, which could lead to expanded approvals for the combination therapy. Ongoing and future studies will continue to evaluate the efficacy of KEYTRUDA and Padcev across different stages of bladder cancer and other genitourinary cancers. The findings may also prompt further research into combination therapies involving immunotherapy and antibody-drug conjugates, potentially leading to new treatment options for various cancer types.
